vs
Side-by-side financial comparison of QuidelOrtho Corp (QDEL) and TFI International Inc. (TFII). Click either name above to swap in a different company.
TFI International Inc. is the larger business by last-quarter revenue ($921.9M vs $699.9M, roughly 1.3× QuidelOrtho Corp).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
TFI International Inc. is a Canadian transport and logistics company based in Saint-Laurent, Quebec, a borough of Montreal. It operates primarily in Canada, the United States, and Mexico through 4 business segments: less than truckload (LTL), package and courier, logistics, and truckload. It has Canada's largest LTL business, largest trucking fleet, and in 2021 was ranked 6th in terms of revenue among both LTL and truckload North American carriers. Its trucking fleet consists of over 14,000 c...
QDEL vs TFII — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $699.9M | $921.9M |
| Net Profit | $-733.0M | — |
| Gross Margin | — | — |
| Operating Margin | -100.7% | 8.4% |
| Net Margin | -104.7% | — |
| Revenue YoY | -3.7% | — |
| Net Profit YoY | -3583.4% | — |
| EPS (diluted) | $-10.78 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $699.9M | $921.9M | ||
| Q2 25 | $613.9M | $2.0B | ||
| Q1 25 | $692.8M | $2.0B | ||
| Q4 24 | $707.8M | — | ||
| Q3 24 | $727.1M | $1.0B | ||
| Q2 24 | $637.0M | $2.3B | ||
| Q1 24 | $711.0M | $1.9B | ||
| Q4 23 | $742.6M | — |
| Q3 25 | $-733.0M | — | ||
| Q2 25 | $-255.4M | $98.2M | ||
| Q1 25 | $-12.7M | $56.0M | ||
| Q4 24 | $-178.4M | — | ||
| Q3 24 | $-19.9M | — | ||
| Q2 24 | $-147.7M | $117.8M | ||
| Q1 24 | $-1.7B | $92.8M | ||
| Q4 23 | $7.0M | — |
| Q3 25 | -100.7% | 8.4% | ||
| Q2 25 | -29.4% | 8.4% | ||
| Q1 25 | 4.7% | 5.8% | ||
| Q4 24 | -14.2% | — | ||
| Q3 24 | 2.1% | 9.5% | ||
| Q2 24 | -18.4% | 9.2% | ||
| Q1 24 | -247.3% | 8.1% | ||
| Q4 23 | 5.4% | — |
| Q3 25 | -104.7% | — | ||
| Q2 25 | -41.6% | 4.8% | ||
| Q1 25 | -1.8% | 2.9% | ||
| Q4 24 | -25.2% | — | ||
| Q3 24 | -2.7% | — | ||
| Q2 24 | -23.2% | 5.2% | ||
| Q1 24 | -239.9% | 5.0% | ||
| Q4 23 | 0.9% | — |
| Q3 25 | $-10.78 | — | ||
| Q2 25 | $-3.77 | — | ||
| Q1 25 | $-0.19 | — | ||
| Q4 24 | $-2.54 | — | ||
| Q3 24 | $-0.30 | — | ||
| Q2 24 | $-2.20 | — | ||
| Q1 24 | $-25.50 | — | ||
| Q4 23 | $0.11 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.1M | — |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $2.0B | — |
| Total Assets | $5.7B | — |
| Debt / EquityLower = less leverage | 1.23× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $98.1M | — | ||
| Q2 25 | $151.7M | — | ||
| Q1 25 | $127.1M | — | ||
| Q4 24 | $98.3M | — | ||
| Q3 24 | $143.7M | — | ||
| Q2 24 | $107.0M | — | ||
| Q1 24 | $78.5M | — | ||
| Q4 23 | $167.3M | — |
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — | ||
| Q4 23 | $2.3B | — |
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.8B | — | ||
| Q1 25 | $3.0B | — | ||
| Q4 24 | $3.0B | — | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $3.2B | — | ||
| Q1 24 | $3.3B | — | ||
| Q4 23 | $5.0B | — |
| Q3 25 | $5.7B | — | ||
| Q2 25 | $6.4B | — | ||
| Q1 25 | $6.5B | — | ||
| Q4 24 | $6.4B | — | ||
| Q3 24 | $6.8B | — | ||
| Q2 24 | $6.7B | — | ||
| Q1 24 | $6.7B | — | ||
| Q4 23 | $8.6B | — |
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.68× | — | ||
| Q4 23 | 0.45× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-45.5M | — |
| Free Cash FlowOCF − Capex | $-94.7M | — |
| FCF MarginFCF / Revenue | -13.5% | — |
| Capex IntensityCapex / Revenue | 7.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-153.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-45.5M | — | ||
| Q2 25 | $-46.8M | — | ||
| Q1 25 | $65.6M | — | ||
| Q4 24 | $63.7M | — | ||
| Q3 24 | $117.9M | — | ||
| Q2 24 | $-97.9M | — | ||
| Q1 24 | $-700.0K | — | ||
| Q4 23 | $80.4M | — |
| Q3 25 | $-94.7M | — | ||
| Q2 25 | $-84.3M | — | ||
| Q1 25 | $9.4M | — | ||
| Q4 24 | $16.5M | — | ||
| Q3 24 | $71.4M | — | ||
| Q2 24 | $-133.2M | — | ||
| Q1 24 | $-66.8M | — | ||
| Q4 23 | $31.8M | — |
| Q3 25 | -13.5% | — | ||
| Q2 25 | -13.7% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 9.8% | — | ||
| Q2 24 | -20.9% | — | ||
| Q1 24 | -9.4% | — | ||
| Q4 23 | 4.3% | — |
| Q3 25 | 7.0% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 8.1% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 6.4% | — | ||
| Q2 24 | 5.5% | — | ||
| Q1 24 | 9.3% | — | ||
| Q4 23 | 6.5% | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 11.49× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
TFII
Segment breakdown not available.
